The market has a moderate buy the dip mentality today. I don’t suggest I have any strong opinion as to whether this will continue. Rationally, it should. The ISM report today was better than expected. There is an Indian trade deal which should be positive for IT demand. But there has been loads of technical…
We sold the remaining 400 shares we had of GitLab this morning. We sold the shares at $41.09 and this raised $16, 435. In the course of researching the article I am writing about Nebius, I came across a company called Cursor. While not an exact competitor, Cursor has increased its ARR by 10X to $1 billion…
I am getting this to subscribers a bit later than normal-last week’s post ran too long so this was not included. Then too, with the excitement with regards to Oracle and Nebius, my scheduling got severely impacted. Here is the list: the first 3 ideas are the companies that have just reported, i.e. Oracle, Nebius…
Confluent has once again disappointed its shareholders, and that includes me, and after several quarters of what I would describe as proof of the company’s inability to monetize its technology, my patience is exhausted. For the second time in 18 months, the company described a usage optimization paradigm amongst its cloud native customers that is…
Summary Veeva delivered a standout quarter, raising guidance and demonstrating accelerating growth, with Crossix and Vault CRM driving strong revenue and margin outperformance. Despite macro and competitive risks, I see Veeva’s competitive position strengthening, especially as migrations to Vault CRM and new AI offerings gain traction. VeevaAI, launching in December, is poised to boost growth…
Summary Veeva share price has recently been battling concerns that Salesforce will become a more aggressive competitor and take meaningful market share in Veeva’s CRM space. Veeva’s financial performance remains strong with high non-GAAP operating margins and free cash flow margins around 40%, positioning it as a GARP investment. The company’s strategy includes expanding its…
Sales of 100 shares of Veeva (entire position); 200 shares of Procore and 320 Nutanix-Total Sales of Purchase of 300 shares of UiPath; 500 Shares of Nu Holdings; 633 shares of Pagaya; 400 shares of SentinelOne and 30 shares of Zscaler As we indicated in the post we sent on Thursday, we decided to make…
Sale of 140 shares of Impinj (Entire Position) Purchase of 200 shares of Global One and 100 shares of Veeva We are making some portfolio changes in the Ticker Target High Growth Portfolio. We are selling our position in Impinj. The shares have been a yo-yo in the period since we have owned them. At…
There have been lots of earnings the past few days, and some other news as well. Now, if only ChatGPT was up to the task…I have to confess as enthused as I am about GenerativeAI, it sometimes can compose the most peculiar sentences. I actually had to try to explain to it the difference between…
Summary Veeva is one of the leading software providers to life sciences vertical. Recently growth has slowed, mainly a function of saturation in the company’s historic core of providing CRM solutions to the pharma industry. The company is in the process of moving its CRM solution to its own platform Vault, and this is likely…